AELIX: Next stage with new CEO
Before joining the biotechnology company, Melanie Rolli was CEO at PIQUR Therapeutics in Basel, which specializes in drugs for oncology and dermatology. Prior to PIQUR, Dr Rolli spent 14 years at Novartis Pharmaceutical AG. There she held positions of increasing responsibility in global development, global safety and medical affairs.
Aelix Therapeutics is focused on developing a therapeutic vaccine for HIV patients. The new CEO follows the announcement of positive topline results in a Phase I/II clinical trial in spring 2021.